Retatrutide Side Effects: Safety Signals and Warnings
Retatrutide safety concerns are compound-specific. The main listed side effects are Nausea, Diarrhea, and Vomiting. The main warning signals are Not yet approved for clinical use - investigational only, Risk of gastrointestinal adverse events, especially during dose escalation, and Potential risk of thyroid C-cell tumors based on GLP-1 class warnings.
Direct Answer
Retatrutide now has the strongest reported weight-loss signal in the library: Lilly's Phase 3 TRIUMPH-1 topline data showed -28.3% at 80 weeks and up to -30.3% in a 104-week extension subgroup. It is still investigational and unpublished in full, so tirzepatide remains the approved default; retatrutide is the leading next-generation candidate to watch.
- Evidence grade
- Level B
- Research status
- Phase 3
- Category
- Weight Loss & Metabolic
- Best for
- Weight loss research, obesity pharmacology, metabolic dysfunction-associated steatotic liver disease
Reported Side Effects
- Nausea
- Diarrhea
- Vomiting
- Decreased appetite
- Constipation
- Injection site reactions
Warnings
- Not yet approved for clinical use - investigational only
- Risk of gastrointestinal adverse events, especially during dose escalation
- Potential risk of thyroid C-cell tumors based on GLP-1 class warnings
- Should not be used in patients with a personal or family history of medullary thyroid carcinoma
Known or Plausible Interactions
- Insulin and sulfonylureas (increased hypoglycemia risk)
- Oral medications (delayed gastric emptying may alter absorption)
Regulatory Context
Investigational - not approved for clinical use. Positive Phase 3 TRIUMPH-1 topline results were announced in May 2026, but retatrutide remains available only through clinical trials.
Evidence Snapshot
| Evidence grade | Level B |
|---|---|
| Research status | Phase 3 |
| Best supported outcomes | Body Weight Reduction (Level B), Glycemic Control (Level B), Hepatic Fat Reduction (Level B), and Gastrointestinal Side Effects (Level B) |
| Primary citation count | 3 |
| Last reviewed | 2026-06-01 |
Related Guides
How to Cite This Page
ExaminePeptides. "Retatrutide Side Effects: Safety Signals and Warnings." Last reviewed 2026-06-01. https://examinepeptides.com/answers/retatrutide-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.